Nivolumab has been approved by different regulatory agencies worldwide for the treatment of nSq-NSCLC based on its superiority in Overall Survival (OS) versus docetaxel in CheckMate 057 trial. In a pre-specified subgroup analysis of the same trial, this advantage was confirmed also in KRAS-mutation+ pts but the small number precluded any definitive conclusion. The Italian nivolumab EAP for non-sq-NSCLC might represent an important source of information in that respect. The current analysis describes results of the use of nivolumab in the group of EAP pts with KRAS mutations.
PReal life experience with nivolumab in patients (pts) with advanced non-squamous NSCLC (nSq-NSCLC) exhibiting KRAS mutations: The Italian Expanded Access Program (EAP)
NATOLI, Clara;
2017-01-01
Abstract
Nivolumab has been approved by different regulatory agencies worldwide for the treatment of nSq-NSCLC based on its superiority in Overall Survival (OS) versus docetaxel in CheckMate 057 trial. In a pre-specified subgroup analysis of the same trial, this advantage was confirmed also in KRAS-mutation+ pts but the small number precluded any definitive conclusion. The Italian nivolumab EAP for non-sq-NSCLC might represent an important source of information in that respect. The current analysis describes results of the use of nivolumab in the group of EAP pts with KRAS mutations.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
